Star Scientific IND Blocks Supplement Marketing Options – FDA
This article was originally published in The Tan Sheet
Executive Summary
An FDA warning letter deems Star Scientific’s CigRx and Anatabloc supplements unapproved drugs due to multiple issues, including claims. The firm’s approved IND study for the ingredient also prevents its use in supplements, the agency says.
You may also be interested in...
Industry News Roundup
MediNatura buys Heel Group USA; FDA refuses to file Rock Creek Pharmaceuticals NDI notification; FTC bans businessman from weight-loss industry; AHPA recommends cannabis quality-control regulations; new leadership team at NBTY; FDA cites supplement inflammation claims; and Green Cures signs marketing partners.
Industry News Roundup
MediNatura buys Heel Group USA; FDA refuses to file Rock Creek Pharmaceuticals NDI notification; FTC bans businessman from weight-loss industry; AHPA recommends cannabis quality-control regulations; new leadership team at NBTY; FDA cites supplement inflammation claims; and Green Cures signs marketing partners.
Between A Rock Creek And A Hard Place: Firm Stops Supplement Sales, Weathers Litigation
Rock Creek Pharmaceuticals faces investor and consumer class-action complaints on top of ending sales of its nutritionals following an FDA warning. Moreover, the company name is known more in connection with federal officials’ investigation of the former governor of Virginia than for its products.